Head to Head Comparison: Inhibikase Therapeutics (IKT) and Its Peers

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Inhibikase Therapeutics to similar companies based on the strength of its valuation, earnings, analyst recommendations, profitability, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Inhibikase Therapeutics and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Inhibikase Therapeutics $260,000.00 -$48.26 million -3.80
Inhibikase Therapeutics Competitors $3.56 billion $3.19 billion 562.76

Inhibikase Therapeutics’ competitors have higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Inhibikase Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inhibikase Therapeutics N/A -40.53% -38.44%
Inhibikase Therapeutics Competitors -2,400.69% -221.80% -15.58%

Insider & Institutional Ownership

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Inhibikase Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics 1 2 4 3 2.90
Inhibikase Therapeutics Competitors 7844 13796 25806 1039 2.41

Inhibikase Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 212.50%. As a group, “Pharmaceuticals” companies have a potential upside of 24.67%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Inhibikase Therapeutics is more favorable than its competitors.

Volatility and Risk

Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics’ competitors have a beta of -0.13, indicating that their average share price is 113% less volatile than the S&P 500.

Summary

Inhibikase Therapeutics competitors beat Inhibikase Therapeutics on 7 of the 13 factors compared.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.